Saving Injectables and ICU Care Segment
Aptus Pharma Limited has announced its expansion into the Life-Saving Injectables and ICU Care product category through a regulatory filing dated February 26, 2026. The new portfolio will focus on products for severe infections, sepsis, and critical care conditions administered in hospital settings. This strategic move follows the company's recent entry into OTC and Uro Care segments and aligns with its growth strategy to strengthen presence across prescription, institutional, and retail healthcare segments.
